烟碱对氧化震颤素和槟榔碱流涎作用的调节

氧化震颤素和槟榔碱激动唾液腺Ｍ受体剂量依赖性地诱发小鼠流涎,ＥＤ＿（５０）值分别为１１６．２７±２０．１１μｇ／ｋｇｓｃ和９．０２±１．７５ｍｇ／ｋｇｓｃ。烟碱（０．５,１．０ｍｇ／ｋｇｓｃ间隔５ｍｉｎ）预处理后,氧化震颤素和槟榔碱诱发小鼠流涎作用的量效曲线显著左移,ＥＤ＿（５０）值分别降为４３．２５±１１．５２μｇ／ｋｇｓｃ和４．７５±０．７６ｍｇ／ｋｇｓｃ。以美加明阻断Ｎ受体功能后,能对抗烟碱调节Ｍ受体激动剂的流涎作用。以氯化锂抑制肌醇磷酸酶后,能增强烟碱调节Ｍ激动剂的流涎作用。提示烟碱增强唾液腺Ｍ受体对其激动剂的反应性和敏感性,可能与神经元性Ｎ受体干扰唾液腺磷脂酰肌醇代谢有关。     

海人酸诱发癫痫敏感性长期增强的形成与维持

用海人酸（ＫＡ）１０ｍｇ／ｋｇ给Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ大鼠皮下注射，注射后０－３０ｍｉｎ内，动物出现凝视和湿狗样抖动；３０－１２０ｍｉｎ出现时间依赖的癫痫行为；２ｈ后，出现自发反复癫痫发作，４ｈ减弱，８ｈ停止。然后，在上述急性癫痫发作后８，４，２，１周，及１－６ｄ时，分别用阈下剂量ＫＡ（５ｍｇ／ｋｇ）检测癫痫敏感性。结果表明，ＫＡ诱发动物急性癫痫发作后，其癫痫敏感性长期增强，且形成过程是在Ｋ     

头端延髓腹外侧区血管加压素在刺激中脑dPAG区诱发防御性升压反应中的…

雄性Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ大鼠,用乌拉坦（７００ｍｇ／ｋｇ）和氯醛糖（３０ｍｇ／ｋｇ）腹腔麻醉。在双侧头端延髓腹外侧区（ｒＶＬＭ区）每侧微量注射血管加压素（ＡＶＰ）（１０ｐｍｏｌ／０．１μｌ）可引起平均动脉压（ＭＢＰ）升高,心率（ＨＲ）变化不明显,每侧微量注射ＡＶＰ的Ｖ１受体拮抗剂ｄ（ＣＨ２）５［Ｔｙｒ（Ｍｅ）＾２］ＡＶＰ（０．１ｎｍｏｌ／０．１μｌ）后ＭＢＰ和ＨＲ无明显变化。若预先在ｒＶＬ     

MS-551抗缺血性室性心律失常的实验研究

目的：研究新型Ⅲ类抗心律失常药物ＭＳ－５５１,即１,３二甲基－６「２－（Ｎ－２羟乙基－３－４硝苯丙氨基）乙氨基」－２,４（１Ｈ,３Ｈ）－盐酸嘧啶二酮（ＭＳ）,对麻醉犬心肌的电作用和对缺血性室性心律失常的防治效果。方法：测定用药（ＭＳ首剂０．５ｍｇ／ｋｇ于５ｍｉｎ内静推,维持量０．５ｍｇ／ｋｇ静滴３０ｍｉｎ）前后下沉犬心肌房室不应期,并观察ＭＳ「首剂０．３ｍｇ／ｋｇ于５ｍｉｎ内静推,维持量０．５ｍｇ     

新克痛宁术后镇痛效果观察

目的了解眼镜蛇毒制剂新克痛宁对术后镇痛效果。方法对７２例胫腓骨折病人,在连续硬膜外阻滞麻醉下行切开复位内固定术,术后随机分为４组（每组１８例）向硬膜外腔注药：Ａ组新克痛宁０．２５ＩＵ／ｋｇ;Ｂ组新克痛宁０．１２５ＩＵ／ｋｇ加０．５％利多卡因液１０ｍｌ;Ｃ组吗啡２ｍｇ;Ｄ组吗啡１ｍｇ加０．５％利多卡因液１０ｍｌ。结果镇痛持续时间Ａ、Ｂ组明显延长,Ａ与Ｂ组分别为（４１２±２８）ｍｉｎ,与Ｃ、Ｄ组比较差异显著（Ｐ＜０．０５）。注药后３０～１２０ｍｉｎ,患肢足背皮肤温度,Ａ、Ｂ组亦高于Ｃ、Ｄ组（Ｐ＜０．０５）,且无不良反应。结论新克痛宁术后镇痛效果比吗啡好。     

杧果采后生理研究

适期采收的果．采收时呼吸速率为２３．２ｍｇＣＯ２·ｋｇ（－１）ｈ（－１）果皮深绿色．果肉硬度＞３０Ｐ／ｃｍ２．置室温下（３０℃）８ｄ出现呼吸高峰,速率１３２．９ｍｇＣＯ２·ｋｇ（－１）ｈ（－１）,果皮的颜色黄绿各半．果肉硬度８—９Ｐ／ｃｍ２。采后１２—１４ｄ果实达到完熟,果皮金黄色,硬度＜３Ｐ／ｃｍ２,呼吸速率下降到３９—４５ｍｇＣＯ２·ｋｇ（－１）ｈ（－１）。试验结果还表明．可溶性糖、还原糖、非还原糖、固形物等含量．均在采后第５天明显增高,果皮从深绿转为淡绿色。可溶性糖在采后第１４天增至最高．达９．９２％,此时可滴定酸度下降至０．１４％．ＰＨ值升至６．１５,此时为果实的最佳供食状态．生产上可据此为制定果贮藏措施提供依据．     

应用乙酰胆碱选择性微电极对赛拉嗪抗胆碱作用的观察

应用乙酰胆碱选择性微电极技术,观察到电刺激大鼠的隔内侧核（脉宽０．５ｍｓ,频率１００Ｈｚ,强度４０Ｖ）,可显著提高海马ＣＡ１区乙酰胆碱的含量。赛拉嗪（２．０和６．０ｍｇ·ｋｇ－１）及咪唑克生（０．６ｍｇ·ｋｇ－１）能分别抑制或促进上述作用,而且咪唑克生可完全拮抗赛拉嗪（６．０ｍｇ·ｋｇ－１）对电刺激隔内侧核增加海马ＣＡ１区乙酰胆碱含量效应的抑制作用。结果提示,赛拉嗪具有抗胆碱作用,且其抗胆碱作用可能亦由α２－受体介导。     

侧脑室注射牛磺酸对脑内生长抑素含量的影响

目的和方法：利用放射免疫分析技术,测定侧脑室注射不同浓度牛磺酸后１０ｍｉｎ、３０ｍｉｎ等不同时间内,大鼠部分脑区及血浆生长抑素含量的变化。结果：①侧脑室注射牛磺酸４０ｇ／Ｌ５μｌ１０ｍｉｎ后,垂体、下丘脑及桥延部生长抑素含量明显增加（Ｐ〈０．０５￣０．０１）;３０ｍｉｎ后,垂体、桥延部生长抑素含量恢复正常;②侧脑室注射４００ｇ／Ｌ５μｌ牛磺酸后,下丘脑生长抑系含量较对照组升高（Ｐ〈０．０５￣０．０     

烟碱对氨甲酰胆碱降低心率和血压作用的调节

在乌拉坦麻醉的大鼠上,间隔５ｍｉｎ３次静注烟碱１７５ｕｇ／ｋｇ,首剂烟碱后,动物对其负性心认综合利用科生急性耐受,但对其降压作用不产生急性耐受。相同条件下,间隔５ｍｉｎ３次静注氢甲酰胆碱１０ｕｇ／ｋｇ,动物对其负性心率和降压作用均不产生急性耐受。在对烟碱负性心率作用产生急性耐受的大鼠上,静注氨甲酰胆碱５和１０ｕｇ／ｋｇ,负性心率作用显著增强,但降压作用无显著变化。提示烟碱诱导动物对其负性心率作用产     

维拉帕米对大鼠浸水应激性胃溃疡的影响

目的和方法：尖激性胃溃疡模型,研究维拉帕米ｉｐ对大鼠应激性溃疡的影响及其作用机制。结果：（１）给拉帕米（５～２０ｍｇ／ｋｇ）可抑制大鼠浸水应激性胃溃疡的发生。（２）维拉帕米（１０ｍｇ／ｋｇ）可抑制浸水应激大鼠胃液,胃酸的分泌及胃的运动,而对胃粘液的分泌无影响;（３０浸水庆激后大鼠胃粘膜一氧化氮合成酶（ＮＯＳ）活性和一氧化氮（ＮＯ）含量均明显降人氏,维拉帕米（１０ｍｇ／ｋｇ）可抑制应激导致的ＮＯＳ活     

Thyrotropin-Releasing Hormone Reduces myo-Inositol Content in Rat Cerebellum Pretreated with Lithium

The effect of thyrotropin-releasing hormone (TRH) and lithium on myo-inositol metabolism has been assessed in rat cerebral cortex, cerebellar cortex, and sciatic nerves. Sprague-Dawley male rats were injected subcutaneously with 10 mEq/kg of LiCl and intraperitoneally with 10 mg/kg of TRH-tartrate, alone or in combination. Either lithium or TRH alone had little effect on the myo-inositol concentration in cerebellar cortex, whereas the combination of lithium and TRH significantly lowered the level. The myo-inositol level of cerebellar cortex reached its nadir (70% of values in untreated control rats) 30 min after addition of TRH and then returned to the control level at 90 min. In cerebral cortex, both lithium alone and lithium plus TRH significantly reduced the myo-inositol level. No effect was seen on the myo-inositol concentration in sciatic nerves with these regimens. These results suggested that the pharmacological dose of TRH activated phosphatidylinositol turnover in rat cerebellar cortex and subsequently reduced the myo-inositol level in the presence of lithium.     

Lithium Effects on Inositol Phospholipids and Inositol Phosphates: Evaluation of an In Vivo Model for Assessing Polyphosphoinositide Turnover in Brain

Administration of lithium chloride to rats injected intracerebrally with [3H]inositol led to time- and dose-dependent increases in levels of labeled inositol monophosphates in brain. Quantitative analysis of the inositol phosphates by ion chromatography revealed 37- and 20-fold increases in the mass of myo-inositol 1-phosphate and 4-phosphate, respectively, at 4 h intraperitoneal after injections of 6 mEq/kg of lithium chloride. Albeit to a much lesser extent, lithium administration also resulted in an increase in the level of myo-inositol, 1,4-bisphosphate in brain. The lithium-induced increase in content of labeled inositol monophosphates was marked by a concomitant decrease in content of labeled inositol, and after injections of high doses of lithium, e.g., 10 mEq/kg, this was followed by a general decrease in labeling of the inositol phospholipids. In general, animals injected with [3H]inositol but not lithium did not reveal obvious differences in labeling of inositol monophosphates on stimulation by mecamylamine or pilocarpine. However, when animals were injected with [3H]inositol and then lithium, there were large increases in the levels of labeled inositol monophosphates on administration of these compounds. Administration of atropine to the lithium-treated mice led to a partial reduction in the amount of labeled inositol monophosphates accumulated due to the administration of lithium alone. Furthermore, atropine was able to block the pilocarpine-induced increase in level of labeled inositol monophosphates. These results demonstrate the suitable use of the radiotracer technique together with lithium administration for assessing the effects of drugs and receptor agonists on the signaling system involving polyphosphoinositide turnover in brain.     

Effects of Systemically Administered Lithium on Phosphoinositide Metabolism in Rat Brain, Kidney, and Testis

A single subcutaneous dose of 10 mEq/kg LiCl gives rise to an increase in the cerebral cortex level of myo-inositol-1-P (I1P) that closely follows cortical lithium levels and, at maximum, is 40-fold above the control value. Kidney and testis show smaller increases in I1P level following LiCl administration. The I1P level is still sixfold greater than that of untreated rat cortex 72 h later. In cortex, parallel increases also occur in myo-inositol-4-P (I4P) and myo-inositol 1,2-cyclic-P (cI1,2P), whereas myo-inositol-5-P (I5P) remains unchanged. The cortical increases in I1P and I4P levels are partially reversed by administering 150 mg/kg of atropine 22 h after the LiCl, treatment that does not affect cI1,2P. When doses of LiCl from 2 to 17 mEq/kg are given, the cerebral cortex levels of I1P and myo-inositol, measured 24 h later, are found to reach a plateau at about 9 mEq/kg of LiCl, whereas cortical lithium levels continued to increase with greater LiCl doses. Levels of all three of the brain phosphoinositides are unchanged by the 10 mEq/kg LiCl dose, as is the uptake of 32Pi into these lipids. Chronic dietary administration of LiCl for 22 days showed that the effects of lithium on I1P and myo-inositol levels persist for that period. Over the course of the chronic administration of the lithium, levels of I1P, myo-inositol, and of lithium in cortex remained significantly correlated. We believe that these increases in inositol phosphates result from endogenous phosphoinositide metabolism in cerebral cortex and that lithium is capable of modulating that metabolism by reducing cellular myo-inositol levels. The size of the effect is a function of both lithium dose and the degree of stimulation of receptor-linked phosphoinositide metabolism. This property of lithium may explain part of its ability to moderate the symptoms of mania. Our chronic study suggests that prolonged administration of LiCl does not result in compensatory changes in myo-inositol-1-P synthase or myo-inositol-1-phosphatase.     

Differential Uptake of Lithium Isotopes by Rat Cerebral Cortex and Its Effect on Inositol Phosphate Metabolism

Twenty hours following the subcutaneous administration of 5 mEq/kg doses of 6LiCl and 7LiCl to two groups of rats, the cerebral cortex molar ratio of 6Li+/7Li+ is 1.5. The effects of the lithium isotopes on cortex myo-inositol and myo-inositol-l-phosphate levels are the same as we have reported earlier: a Li+ concentration-dependent lowering of myo-inositol and increase in myo-inositol-1-phosphate. Thus 6LiCl, when administered at the same dose as 7LiCl, produces the larger effect on inositol metabolism. When the 6LiCl and 7LiCl doses were adjusted to 5 mEq/kg and 7 mEq/kg, respectively, the cortical lithium myo-inositol and myo-inositol-1-phosphate levels of each group of animals became approximately equal, suggesting that the isotope effect occurs at the level of tissue uptake, but not on inositol phosphate metabolism. The inhibition of myo-inositol-1-phosphatase by the two lithium isotopes in vitro showed no differential effect. The isotope effect on cerebral cortex uptake of lithium is in the same direction as that reported by others for erythrocytes and for the CSF/plasma ratio, but of larger magnitude.     

Acute reduction of brain substance P induced by nicotine

Ten minutes after a single injection of 0.8 mg/kg nicotine SC (free base) the level of substance P-like immunoreactivity (SPLI) was reduced by 61–73% in rat caudate-putamen, nucleus accumbens, and olfactory tubercle, with smaller and not significant reductions in the frontal cortex, substantia nigra, and ventral tegmental area. The nicotinic receptor antagonist mecamylamine (1.0 mg/kg IP) prevented the reductions in SPLI. The rapidity and the degree of the changes in SPLI after nicotine exceed those previously reported for other agents and implicate substance P neurotransmission as a major component of nicotinic action.Preliminary data were presented at the 17th annual meeting of the American Society for Neurochemistry, Montreal, 1986 (1).     

Behavioral and receptor binding studies of phencyclidine (PCP) and lithium interaction in the rat

Three groups of female Sprague-Dawley rats (n = 4) were conditioned to drink water during a daily 2 hr session. The water was then changed to a solution of 1.0 mg/ml lithium chloride producing average doses between 62.9 and 72.1 mg/kg/day for Groups I and II. These rats were challenged with 4 mg/kg PCP i.p. before and during lithium treatment. Group I was tested for spontaneous locomotor activity in the open field apparatus. Lithium alone did not affect activity. After 1, 2, and 3 weeks of chronic lithium, PCP-induced activity increased 2.1, 1.7, and 2.8 fold, respectively, relative to PCP-induced activity during limited access to water only. Whole brain homogenates from Group II, after one week of chronic lithium, were used for receptor binding experiments using [3H] PCP; Group III served as water controls. The Kd (nM +/- S.E.M.) was not different in untreated (146.39 +/- 18.95) and lithium-treated (181.22 +/- 14.35) rats. The Bmax (pmole/mg protein +/- S.E.M.), however, was increased 48% (p less than 0.01) from 1.50 +/- 0.08 to 2.22 +/- 0.10 after lithium. These preliminary results suggest that chronic administration of lithium modifies the behavioral effects of PCP possibly via alterations at the receptor level.     

Mutagenic action of cadmium on the sex cells of male mice

Possible mutagenic effect of cadmium chloride was studied by determining the frequency of dominant lethal mutations induced in germ cells of male mice. Water solution of CdCl2 was injected intraperitoneally to male mice at doses of 1.0, 2.0 and 4.0 mg/kg. The results obtained did not reveal any mutagenic effect of this compound. The dose of 4.0 mg/kg CdCl2 resulted in the death of spermatocytes and spermatogonia and the sterility of male mice. Cadmium chloride at a dose of 2.0 mg/kg did not affect the frequency of dominant lethal mutation induced by gamma-rays 60Co at a dose of 450 r in germ cells of male mice.     

Subacute and Chronic In Vivo Lithium Treatment Inhibits Agonist- and Sodium Fluoride-Stimulated Inositol Phosphate Production in Rat Cortex

We have investigated the effects of in vivo lithium treatment on cerebral inositol phospholipid metabolism. Twice-daily treatment of rats with LiCl (3 mEq/kg) for 3 or 16 days resulted in a 25-40% reduction in agonist-stimulated inositol phosphate production, compared with NaCl-treated controls, in cortical slices prelabelled with [3H]inositol. A small effect was also seen with 5-hydroxytryptamine (5-HT) 24 h after a single dose of LiCl (10 mEq/kg). Dose-response curves to carbachol and 5-HT showed that lithium treatment reduced the maximal agonist response without altering the EC50 value. This inhibition was not affected by the concentration of LiCl in the assay buffer. Stimulation of inositol phosphate formation by 10 mM NaF in membranes prepared from cortex of 3-day lithium-treated rats was also inhibited, by 35% compared with NaCl-treated controls. Lithium treatment did not alter the kinetic profile of inositol polyphosphate formation in cortical slices stimulated with carbachol. Muscarinic cholinergic and 5-HT2 bindings were unaltered by lithium, as was cortical phospholipase C activity and isoproterenol-stimulated cyclic AMP formation. [3H]Inositol labelling of phosphatidylinositol 4,5-bisphosphate was significantly enhanced by 3-day lithium treatment. The results, therefore, indicate that subacute or chronic in vivo lithium treatment reduces agonist-stimulated inositol phospholipid metabolism in cerebral cortex; this persistent inhibition appears to be at the level of G-protein-phospholipase C coupling.     

Effects of local and repeated systemic administration of (−)nicotine on extracellular levels of acetylcholine,norepinephrine, dopamine,and serotonin in rat cortex

Systemically administered (–)nicotine (0.2–1.2 mg/kg, s.c.) significantly increased the release of acetylcholine (ACh), norepinephrine (NE) and dopamine (DA) in rat cortex. The lowest dose of (–)nicotine examined (0.2 mg/kg, s.c) also significantly elevated extracellular serotonin (5-HT) levels, and the maximal increases of extracellular ACh (122% at 90 min post injection) and DA levels (249% at 120 min post-injection) were observed following this dose. In contrast, the maximal increase of NE release (157% at 30 min post-injection) was observed following the highest dose of (–)nicotine injected (1.2 mg/kg, s.c.). This higher dose consistently produced generalized seizures. Repeating the (–)nicotine (0.58 mg/kg, s.c.) injection four hours after the first administration significantly elevated extracellular NE levels and also appeared to increase DA and CCh release. In addition, extracellular ACh and DA levels increased significantly in the dialysate after (–)nicotine was administered directly to the neocortex through the microdialysis probe membrane. Norepinephrine levels appeared to be elevated in the cortex following local administration as well.     

Regulation of Histamine Turnover via Muscarinic and Nicotinic Receptors in the Brain

To clarify the regulation of central histaminergic (HAergic) activity by cholinergic receptors, the effects of drugs that stimulate the cholinergic system on brain histamine (HA) turnover were examined, in vivo, in mice and rats. The HA turnover was estimated from the accumulation of tele-methylhistamine (t-MH) during the 90-min period after administration of pargyline (65 mg/kg, i.p.). In the whole brain of mice, oxotremorine, at doses higher than 0.05 mg/kg, s.c., significantly inhibited the HA turnover, this effect being completely antagonized by atropine but not by methylatropine. A large dose of nicotine (10 mg/kg, s.c.) also significantly inhibited the HA turnover. This inhibitory effect was antagonized by mecamylamine but not by atropine or hexamethonium. A cholinesterase inhibitor, physostigmine, at doses higher than 0.1 mg/kg, s.c., significantly inhibited the HA turnover. This effect was antagonized by atropine but not at all by mecamylamine. None of these cholinergic antagonists used affected the steady-state t-MH level or HA turnover by themselves. In the rat brain, physostigmine (0.1 and 0.3 mg/kg, s.c.) also decreased the HA turnover. This inhibitory effect of physostigmine was especially marked in the striatum and cerebral cortex where muscarinic receptors are present in high density. Oxotremorine (0.2 mg/kg, s.c.) and nicotine (1 mg/kg, s.c.) also decreased the HA turnover in the rat brain. However, these effects showed no marked regional differences. These results suggest that the stimulation of central muscarinic receptors potently inhibits the HAergic activity in the brain and that strong stimulation of central nicotinic receptors can also induce a similar effect.